drugset / Trial / NCT00116402

A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations

NCT00116402

Phase 1 Completed 15 enrolled University of Chicago GlaxoSmithKline · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the blood and airway of subjects with mild to moderate COPD while undergoing standard treatment.

Timeline

Start
2005-01
Primary completion
2009-09
Completion
2009-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluticasone Other / unclassified 220 ug
Comparator Salmeterol Other / unclassified 50 ug